# Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

> **NCT02221739** · PHASE1,PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 39 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Ipilimumab
- **RADIATION:** Radiotherapy (IMRT or 3-D CRT)

## Key facts

- **NCT ID:** NCT02221739
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2015-04-15
- **Final completion:** 2015-10-27
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221739, "Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02221739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*